Publications

María Esther Larrea Leoz publications

65 results

2026

  1. Fluidity as a key determinant of stability in PEGylated lipid nanoparticles loaded with a TLR7 agonist

    International Journal of Pharmaceutics, Vol. 688

  2. Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden

    Advanced Healthcare Materials, Vol. 15, Núm. 30

  3. Leishmanicidal Action of the Peptides 19-4LF, 19-2.5 and 19-2.5LF Topically Administered on Cutaneous Lesions Caused by Leishmania major

    Pharmaceutics, Vol. 18, Núm. 3

2025

  1. The Role of BRCT Domain from LmjPES in Leishmania major Pathogenesis

    Biomolecules, Vol. 15, Núm. 8

2022

  1. Effect of topical berberine in murine cutaneous leishmaniasis lesions

    Journal of Antimicrobial Chemotherapy, Vol. 77, Núm. 4, pp. 1072-1081

  2. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis

    Pharmaceutics, Vol. 14, Núm. 11

  3. The BRCT Domain from the Homologue of the Oncogene PES1 in Leishmania major (LmjPES) Promotes Malignancy and Drug Resistance in Mammalian Cells

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

2021

  1. Changes in the nanoparticle uptake and distribution caused by an intramacrophagic parasitic infection

    Nanoscale, Vol. 13, Núm. 41, pp. 17486-17503

  2. In leishmania major, the homolog of the oncogene pes1 may play a critical role in parasite infectivity

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

2020

  1. Berberine-loaded liposomes for the treatment of leishmania infantum-infected balb/c mice

    Pharmaceutics, Vol. 12, Núm. 9, pp. 1-18

  2. LmjF.22.0810 from leishmania major modulates the TH2-type immune response and is involved in leishmaniasis outcome

    Biomedicines, Vol. 8, Núm. 11, pp. 1-17

2019

  1. Leishmanicidal activity of isoselenocyanate derivatives

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 2

  2. The novel serine/threonine protein kinase lmjf.22.0810 from Leishmania major may be involved in the resistance to drugs such as paromomycin

    Biomolecules, Vol. 9, Núm. 11

2018

  1. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions

    Journal of Dermatological Science, Vol. 92, Núm. 1, pp. 78-88

  2. TMEM173 Alternative Spliced Isoforms Modulate Viral Replication through the STING Pathway

    ImmunoHorizons, Vol. 2, Núm. 11, pp. 363-376

2017

  1. Construction of Two mCherry Plasmids (pXG-mCherry) for Transgenic Leishmania: Valuable Tools for Future Molecular Analysis

    Journal of Parasitology Research, Vol. 2017

  2. Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.

    International Journal of Pharmaceutics, Vol. 533, Núm. 1, pp. 236-244

2016

  1. A versatile vector for in vivo monitoring of type I interferon induction and signaling

    PLoS ONE, Vol. 11, Núm. 3

  2. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance

    Journal of Medical Virology, Vol. 88, Núm. 5, pp. 843-851

  3. Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function

    OncoImmunology, Vol. 5, Núm. 8